NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
December 14, 2022 07:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
December 14, 2022 01:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
October 18, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
Two Day FDA (Food and Drug Administration) Drug Approval Process Training Course: Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (October 10-11, 2022)
September 28, 2022 08:13 ET
|
Research and Markets
Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The...
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of an Investigational New Drug or “IND” Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder
June 01, 2022 06:00 ET
|
InvestmentPitch Media and FSD Pharma
VANCOUVER, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company dedicated to building a portfolio of assets and...
Worldwide Preclinical CRO Industry to 2026 - Featuring Eurofins Scientific, MD Biosciences and PPD Among Others
December 01, 2021 09:18 ET
|
Research and Markets
Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Preclinical CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
October 07, 2021 17:45 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and...
ROSEN, A RESPECTED AND LEADING FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – PTE
September 29, 2021 16:08 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Growing Research and Development Pipelines of Emerging Biopharmaceutical and Niche Technology Providers Drive Competitive Intensity
September 06, 2021 04:28 ET
|
Research and Markets
Dublin, Sept. 06, 2021 (GLOBE NEWSWIRE) -- The "Global Drug Discovery and Early Development Outsourcing Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report...
Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
August 17, 2021 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247...